Navigation Links
A new synthetic amino acid for an emerging class of drugs
Date:8/31/2014

One of the greatest challenges in modern medicine is developing drugs that are highly effective against a target, but with minimal toxicity and side-effects to the patient. Such properties are directly related to the 3D structure of the drug molecule. Ideally, the drug should have a shape that is perfectly complementary to a disease-causing target, so that it binds it with high specificity. Publishing in Nature Chemistry, EPFL scientists have developed a synthetic amino acid that can impact the 3D structure of bioactive peptides and enhance their potency.

Peptides and proteins as drugs

Many of the drugs we use today are essentially naturally-occurring peptides (small) and proteins (large), both of which are made up with the amino acids found in all living organisms. Despite the enormous variety of peptides and proteins, there are only twenty natural amino acids, each with a different structure and chemical properties. When strung together in a sequence, amino acids create peptides and proteins with different 3D structures and, consequently, different biological functions.

Until recently, the vast majority of amino acid-based drugs were the kinds occurring in nature: hormones such as insulin, antibiotics such as vancomycin, immunosuppressive drugs such as cyclosporine etc. But the mounting burden of diseases means that newer and more effective medications must be developed; for example, bacterial resistance is growing globally, pushing our need for novel antibiotics. One way to address this need is the cutting-edge field of directed evolution, which mimics natural selection in the lab to evolve and develop new peptides and proteins.

A new amino acid for new peptides

The team of Christian Heinis at EPFL has developed a synthetic amino acid whose unique structure can considerably increase the effectiveness of therapeutic peptides and proteins. The synthetic amino acid has a very similar structure to a natural amino acid called cysteine. Cysteine is unique among the twenty natural amino acids because it contains a sulfur group. This allows it to form a bridge with another cysteine, and thereby influence the overall 3D structure and function of a peptide or protein.

The EPFL researchers initially designed five cysteine-like amino acids, all with one crucial change: each one could form two bridges instead of just one. The team achieved this by replacing cysteine's single sulfur group with a branch containing two sulfur groups. After synthesizing the five new amino acids, the team integrated them into the structure of two bioactive peptides, one that inhibits an enzyme implicated in cancer, and one blocking a receptor found in neurons.

Testing only a handful of cyclic peptides with the synthetic amino acid, Heinis' team was able to identify several peptides that showed enhanced activities. The best inhibitor of the neuron receptor was 8-fold improved and the best protease inhibitor had even a 40-fold higher activity.

"This was unexpected", says Christian Heinis. "Usually when you tamper with a natural molecule, you end up making it worse. In this case, we found the exact opposite, which is very exciting."

The emerging class of bicyclic peptides

The team focuses on therapeutics, where they have a strong background in developing "bicyclic" peptides peptides that contain two rings in their structure. Bicyclic peptides have grown into a new class of therapeutic peptides that can be used on disease target that conventional small molecules or large antibodies cannot reach. Heinis' group has generated bicyclic peptides against a range of disease targets using directed evolution. "In our work with bicyclic peptides, we learned that wide structural diversity in peptide libraries is key for achieving good binding. With this new amino acid, it is possible to produce highly diverse peptide structures."

Heinis aims now to use the new amino acid in directed evolution experiments. Its structural features and its ability to efficiently make cyclic peptides makes the synthetic amino acid a promising candidate for developing new, effective polycyclic peptides for targeted therapy.


'/>"/>

Contact: Nik Papageorgiou
n.papageorgiou@epfl.ch
41-216-932-105
Ecole Polytechnique Fdrale de Lausanne
Source:Eurekalert

Related biology news :

1. Synthetic molecule makes cancer self-destruct
2. Postcards from the photosynthetic edge
3. Eurofins Genomics and AmpTec close distribution agreement for very long synthetic RNAs
4. Synthetic triterpenoids show promise in preventing colitis-associated colon cancer
5. An ecological risk research agenda for synthetic biology
6. Synthetic biology still in uncharted waters of public opinion
7. Synthetic gene circuits pump up cell signals
8. Math modeling integral to synthetic biology research
9. Synthetic biology lab backed by £2 million award
10. Rice synthetic biologists shine light on genetic circuit analysis
11. NPL scientists blend synthetic air to measure climate change
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/4/2019)... ... April 03, 2019 , ... R3 Stem ... at its nationwide Centers of Excellence. R3 wants patients to feel secure when ... To protect patients from Centers that use inferior regenerative biologics, protocols or amounts, ...
(Date:3/29/2019)... ... March 28, 2019 , ... In the wake ... programme entirely dedicated to Chinese biobanks was launched in July 2018, in an ... the Biobank Branch, China Medicinal Biotech Association (BBCMBA). The one-year pilot programme offered ...
(Date:3/27/2019)... ... 2019 , ... Evan Holden , a shareholder in the Atlanta ... at the National Academy of Sciences (NAS) Roundtable on Biomedical Engineering Materials Applications (BEMA), ... firm’s award-winning Pharmaceutical, Medical Device & Health Care Litigation Practice , addressed, “Medical ...
Breaking Biology News(10 mins):
(Date:4/9/2019)... ... 09, 2019 , ... The American Society of Gene & Cell Therapy ... including a new addition to the presidential line of succession, at the 22nd ... Society's leadership team for a three-year term (2019-2021). , All five incoming members of ...
(Date:4/4/2019)... ... April 03, 2019 , ... LeadingBiotech, an exclusive ... dialogue, today announces its Boston CEO conference to be held May 28-29, 2019 ... and opportunities with high-level panels and discussions from past, present and future change-makers. ...
(Date:3/23/2019)... ... March 22, 2019 , ... uBiome has awarded microbiome ... of researchers at Nnamdi Azikiwe University in Anambra State, Nigeria led by Dr. ... the Department of Medical Laboratory Sciences and Deputy Provost, College of Health Sciences. ...
(Date:3/19/2019)... ... March 19, 2019 , ... Konica ... today announced the formation of their inaugural Scientific Advisory Board. , ... that takes into account individual variability in genes, environment, and lifestyle to more ...
Breaking Biology Technology: